KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.

PubWeight™: 1.48‹?› | Rank: Top 4%

🔗 View Article (PMID 20049644)

Published in Ann Surg Oncol on January 05, 2010

Authors

Antoine Italiano1, Isabelle Hostein, Isabelle Soubeyran, Thibault Fabas, Daniel Benchimol, Serge Evrard, Jean Gugenheim, Yves Becouarn, René Brunet, Marianne Fonck, Eric François, Marie-Christine Saint-Paul, Florence Pedeutour

Author Affiliations

1: Laboratory of Solid Tumors Genetics, Nice University Hospital, Nice, France. italiano@bergonie.org

Articles citing this

Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer (2011) 2.16

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol (2014) 1.76

RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg (2013) 1.34

Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol (2014) 1.28

Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg (2012) 1.17

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer (2012) 1.16

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist (2011) 1.11

Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep (2015) 1.02

Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis (2011) 0.97

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med (2012) 0.91

Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Invest New Drugs (2010) 0.89

Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis (2011) 0.89

Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89

PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med (2013) 0.88

Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. Int J Colorectal Dis (2011) 0.87

RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol (2014) 0.85

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncol Lett (2014) 0.84

Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med (2012) 0.84

Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch (2013) 0.83

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol (2016) 0.82

Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases. Cancer Microenviron (2013) 0.82

BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer. PLoS Curr (2010) 0.79

Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Colorectal Dis (2011) 0.78

Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases. J Am Coll Surg (2016) 0.78

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. Br J Cancer (2012) 0.78

Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. Mod Pathol (2016) 0.77

Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases. Liver Cancer (2016) 0.75

Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol (2016) 0.75

Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer. Virchows Arch (2016) 0.75

Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma. Case Rep Oncol Med (2017) 0.75

KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care. Am J Cancer Res (2017) 0.75

Articles by these authors

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol (2010) 7.29

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol (2004) 3.10

Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology (2006) 3.09

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol (2012) 2.62

Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases. Am J Surg Pathol (2006) 2.62

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer (2007) 2.52

MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol (2005) 2.51

Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol (2012) 2.39

Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer (2003) 2.28

Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol (2012) 2.26

Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas. Am J Surg Pathol (2014) 2.23

EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer (2009) 2.14

Use of bioresorbable membranes to reduce abdominal and perihepatic adhesions in 2-stage hepatectomy of liver metastases from colorectal cancer: results of a prospective, randomized controlled phase II trial. Ann Surg (2013) 2.10

Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01

Positioning trocars for performing sleeve gastrectomy. Points of controversy. Obes Surg (2015) 1.90

Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol (2007) 1.88

Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl (2006) 1.86

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res (2008) 1.86

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol (2012) 1.74

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2002) 1.65

Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma (2006) 1.65

Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS (2004) 1.64

Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am J Surg Pathol (2007) 1.63

Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer (2003) 1.61

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59

Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58

C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol (2011) 1.54

Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol (2003) 1.53

Gastric pouch resizing for Roux-en-Y gastric bypass failure in patients with a dilated pouch. Surg Obes Relat Dis (2012) 1.49

Complications of intraoperative radiofrequency ablation of liver metastases. HPB (Oxford) (2010) 1.48

Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer (2003) 1.45

HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer (2008) 1.44

The pig as a preclinical model for intestinal ischemia-reperfusion and transplantation studies. J Surg Res (2012) 1.44

Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One (2010) 1.44

UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res (2007) 1.43

Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes (2012) 1.42

The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am J Gastroenterol (2006) 1.42

Patients with acute liver failure listed for superurgent liver transplantation in France: reevaluation of the Clichy-Villejuif criteria. Liver Transpl (2015) 1.38

Unusual evolution of ciprofloxacin-induced hepatitis revealing a possible link with IgG4-associated autoimmune hepatitis. Dig Liver Dis (2011) 1.38

Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res (2009) 1.34

Internal hernia after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg (2006) 1.33

Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes (2008) 1.30

Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother (2009) 1.30

Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl (2005) 1.28

Matrix metalloproteinase inhibition protects rat livers from prolonged cold ischemia-warm reperfusion injury. Hepatology (2008) 1.27

Caecal volvulus. Am J Surg (2008) 1.27

The role of clips in preventing migration of fully covered metallic esophageal stents: a pilot comparative study. Surg Endosc (2011) 1.26

GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25

Laparoscopic repair of intrathoracic mesenterioaxial volvulus of the stomach in an adult: report of a case. Surg Today (2003) 1.23

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol (2005) 1.22

Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer (2002) 1.22

Laparoscopic sleeve gastrectomy for morbid obesity. World J Gastroenterol (2008) 1.19

Palliative portal vein stent placement in malignant and symptomatic extrinsic portal vein stenosis or occlusion. Cardiovasc Intervent Radiol (2008) 1.19

Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials. Dis Colon Rectum (2006) 1.19

Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet Cytogenet (2006) 1.18

MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol (2011) 1.17

The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One (2012) 1.17

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer (2011) 1.16

Severe pneumonia during primary infection with an atypical strain of Toxoplasma gondii in an immunocompetent young man. J Infect (2005) 1.16

Gas gangrene of the breast: management of a potential life-threatening infection. Arch Gynecol Obstet (2008) 1.15

Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res (2011) 1.14

Revised sleeve gastrectomy: another option for weight loss failure after sleeve gastrectomy. Surg Endosc (2013) 1.11

SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology (2012) 1.10

Primary clear cell sarcoma of the ileum: an uncommon and misleading site. Virchows Arch (2005) 1.10

Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2. Eur J Cancer (2012) 1.10

Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol (2002) 1.09

Ischemia-Reperfusion Injury and Ischemic-Type Biliary Lesions following Liver Transplantation. J Transplant (2012) 1.09

Chromosome size and origin as determinants of the level of CENP-A incorporation into human centromeres. Chromosome Res (2004) 1.09

Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer (2011) 1.08

Assessment of different bariatric surgeries in the treatment of obesity and insulin resistance in mice. Ann Surg (2014) 1.07

Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res (2010) 1.07

Percutaneous jejunostomy and stent placement for treatment of malignant Roux-en-Y obstruction: a case report. Clin Imaging (2006) 1.06

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06

Oncocytic lipoadenoma of the parotid gland: Immunohistochemical and cytogenetic analysis. Pathol Res Pract (2009) 1.06

Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature. BMC Cancer (2010) 1.05

The spectrum of parathyroid gland dysfunction associated with the microdeletion 22q11. Eur J Endocrinol (2006) 1.04

11q13 alterations in two cases of hibernoma: large heterozygous deletions and rearrangement breakpoints near GARP in 11q13.5. Genes Chromosomes Cancer (2003) 1.04

Leiomyosarcoma of the ovarian vein: report of a case. Int Surg (2003) 1.04

A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol (2007) 1.03

Regulation of Bcl-2 and Bcl-xL anti-apoptotic protein expression by nuclear receptor PXR in primary cultures of human and rat hepatocytes. Biochim Biophys Acta (2005) 1.02

Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol (2013) 1.02

Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol (2004) 1.02

Comparison of periodontal and socioeconomic status between subjects with type 2 diabetes mellitus and non-diabetic controls. J Periodontol (2007) 1.02

Single incision laparoscopic surgery cholecystectomy: a preliminary experience. Surg Laparosc Endosc Percutan Tech (2010) 1.01

Validation of a new method of detecting peripheral artery disease by determination of ankle-brachial index using an automatic blood pressure device. Angiology (2004) 1.00

CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol (2012) 1.00